Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland

Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually. Several hundred of these patients are likely to carry known genetic mutations associated with HBOC or LS. Genetic testing for hereditary susceptibility to cancer can prevent many cancer deaths through early identification and engagement in high-risk management care that involves intensive surveillance, chemoprevention and/or prophylactic surgery. However, current rates of genetic testing indicate that many Swiss mutation carriers and their family members do not use cancer genetic services (counseling and/or testing), either due to lack of coordination of care or due to lack of communication about the mutation among family members. Cascade screening identifies and tests family members of a known mutation carrier. It determines whether asymptomatic family members are carriers of the identified mutation and proposes management options to reduce harmful outcomes. Robust evidence of basic science and descriptive population-based studies in Switzerland support the necessity of cascade screening for HBOC and LS. However, translation of this knowledge into public health interventions is lacking. Specific Aims of the CASCADE study are: 1. Survey Index Patients diagnosed with HBOC or LS from clinic-based genetic testing records and determine their cancer status and surveillance practices; needs for coordination of medical care; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to serve as advocates for cancer genetic services for blood relatives. 2. Survey first- and second-degree relatives, and first cousins identified from pedigrees and/or family history records of HBOC and LS Index Patients and determine their cancer and mutation status; cancer surveillance practices; needs for coordination of medical care; barriers and facilitators to using cancer genetic services; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to participate in a study designed to increase use of cancer genetic services. 3. Explore the influence of patient-provider communication about genetic cancer risk on patient-family communication and the acceptability of a family-based communication, coping, and decision support intervention with focus group(s) of mutation carriers and blood relatives.

NCT Number	NCT03124212
Lead Sponsor	University of Basel Collaborators: Kantonal Spital Solothurn, Olten, Kantonal Hospital Lucerne, Lindenhofgruppe, Praxis Medidonna, Centre Hospitalier Universitaire Vaudois (CHUV), Service de Médecine Génétique, 1011 Lausanne, Hôpital du Valais, Institut Central des Hôpitaux, Department of Medical Genetics, 1950 Sion, Medizinische Onkologie, Kantonsspital Olten, 4600 Olten, Medizinische Onkologie, Kantonsspital Luzern, 6000 Luzern
Conditions	Hereditary Breast and Ovarian Cancer, Lynch Syndrome
Enrollment	700 participants
Start Date	2017-04-01
Primary Completion	2035-01-31 (estimated)
Study Completion	2035-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-13